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Abstract
Aims: We sought to evaluate the prognostic impact of age on the procedural results and subsequent clinical
outcomes in patients with multivessel disease (MVD) treated either by coronary artery bypass surgery (CABG) or
by percutaneous coronary intervention (PCI) with or without drug eluting stents, based on data of the Arterial
Revascularisation Therapies Study (ARTS) part I and part II. The potential influence of age in determining the most
appropriate revascularisation strategy for patients with MVD is largely unknown.
Methods and results: Three year clinical outcome of ARTS I patients randomised to PCI with bare metal stent
(BMS) (n= 600) or CABG (n= 605), and matched patients treated by PCI with sirolimus-eluting stents (SES) in
ARTS II (n= 607) were reviewed according to four age quartiles. Endpoints were measured in terms of major
adverse cardiac and cerebrovascular events MACCE) during hospital stay and up to three years. The frequency of
female, diabetes, hypertension, peripheral vascular disease, pulmonary disease, as well as lesion complexity
increased with age. At three years, MACCE free survival was comparable between patients treated by CABG or
SES PCI, regardless of age quartile. The incidence of MACCE was higher among ARTS I BMS treated patients in
all but the second age quartile. This was primarily related to a higher need for repeat revascularisation among BMS
treated patients. However, age, which emerged as a strong independent predictor of MACCE following CABG
(p<0.005), was not predictive of adverse events following PCI. Conversely, diabetes was the strongest independent
predictor of MACCE among PCI treated patients (p<0.02), but didn’t affect three-year outcomes following CABG.
Conclusions: Age seems to influence the CABG outcome in-hospital but not PCI. PCI-SES could offer lower
immediate risk in patients with MVD and comparable long-term outcome as CABG especially in older patients.
The worst outcome of PCI-BMS group is primarily related to the need for repeat revascularisation. Diabetes is the
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Introduction
Coronary artery disease (CAD) is the leading cause of mortality
worldwide. The prevalence of CAD increases with age, and this
coupled with increasing life expectancy has led to a sharp rise in the
number of elderly patients undergoing percutaneous coronary
intervention (PCI) and coronary artery bypass grafting surgery
(CABG).1 In comparison to their younger counterparts, older
patients with CAD usually present with more diffuse atherosclerosis
and a higher plaque burden.2 In addition non-cardiac co-
morbidities such as renal insufficiency and impaired pulmonary
function are also more prevalent with increasing age. This high risk
profile of elderly CAD patients contributes to their increased
complication rates, both after PCI3 and CABG.4 Consequently,
numerous clinical studies have confirmed that a correlation exists
between clinical outcomes from either method of revascularisation,
and the patient’s age.5-9 On the other hand elderly patients have
been shown to derive more benefit from invasive coronary
revascularisation than from optimal medical therapy,9-11 and one
study9 even concluded that elderly patients have a greater absolute
risk reduction associated with revascularisation in comparison with
younger patients. The most appropriate revascularisation procedure
for older or younger patients remains controversial, primarily
through the lack of clinical studies investigating a direct comparison
of both treatment strategies.
The objective of the current investigation was to examine the
prognostic impact of age on the procedural results, and subsequent
early and late clinical outcomes in a contemporary cohort of
patients with MVD treated by either CABG or PCI with or without
drug eluting stents (DES).
Methods
Study population and protocol
The present study is a retrospective analysis of the ARTS I and II trials;
the detailed protocols of both have been previously reported.12,13
Briefly, the study population includes the 1,205 patients from the
ARTS-I study who were randomised to either bare metal stent
(BMS) implantation (n=600) or CABG (n=605), and the 607
patients from the ARTS-II registry who were treated by sirolimus-
eluting stent (SES) implantation. In order to obtain a population
comparable to ARTS-I, patients in ARTS-II were stratified per
clinical site in order to ensure that at least one third of the included
patients had triple vessel disease. All inclusion and exclusion
criteria were the same for both trials, including the upper age limit,
which was 80 years old. Patients were enrolled irrespective of
whether they had stable or unstable angina or silent ischaemia.
They were required to have MVD and at least one other significant
lesion (>50% diameter stenosis) in a different major epicardial
artery suitable for stent implantation. Specific exclusion criteria
included: patients with any prior coronary intervention, left main
stem coronary disease, left ventricular ejection fraction of less than
30%, overt heart failure, history of a cerebrovascular accident,
transmural myocardial infarction in the preceding week, severe
hepatic or renal disease and the need for concomitant major
surgery. All patients gave written informed consent.
The pooled population of ARTS-I and ARTS-II was divided into four
equal quartiles of 453 subjects based on age at trial inclusion. The
first, second, third and fourth quartiles (mean±SD) consisted of
patients <54 years (48.8±4.8 years), 54-62 years (58.5±2.1 years),
62-68 years (65.6±1.9 years), and 68-83 years old (73.3±3.1 years)
respectively. Five patients (3 in ARTS I and 2 in ARTS II) older than
80 years were included.
Data analysis and endpoints
Clinical outcomes in each subgroup were compared according to
the assigned treatment, (CABG, PCI with BMS or PCI with SES) and
analysis was performed on the outcome of each revascularisation
procedure according to age quartiles. The primary endpoint was
defined as the absence of any of the following major adverse
cardiac and cerebral events (MACCE) within three years of inclusion
in the trial: death (all-cause mortality), cerebrovascular accident,
non-fatal myocardial infarction (MI), or any repeat revascularisation
(either PCI or CABG).12,14,15 MACCE rate during hospital stay and at
three years is assessed according to hierarchical classification. In
hierarchical classification, only the worst event was counted as an
event. Single adverse events are reported in a non-hierarchical way.
Events for the present report were counted from the time of
procedure for all the three arms. Complete three-year follow-up was
available for all of the 1,812 study patients.
Statistical analysis
Statistical analysis was performed with SAS 6.12 software (SAS
Institute Inc., Chicago, IL, USA). Continuous variables are
expressed as mean±standard deviation (SD) and compared with
use of Student’s unpaired t-test. Categorical variables were reported
as counts and percentages and compared using the Fisher’s exact
test for pair wise variables or the Chi-square for trend to examine the
impact of age. Longitudinal event rates were evaluated using
Kaplan-Meier estimates and compared with the log-rank test. To
examine the impact of age in each treatment strategy, Cox
Proportional Hazard models in SAS V8.2 was used. Both the age
and the treatment subgroups were tested for interaction with
predictor variables. This analysis was restricted to the MACCE. For
the interaction tests between predictor variables and age group or
treatment group, a likelihood ratio test was used by subtracting the
summed -2log(L) of the “by group” analysis from the -2log(L) of the
stratified (by age and by treatment) analysis, and comparing the
outcome with a Chi-square distribution with the correct number of
degrees of freedom. In case of a p-value <0.05 for the interaction,
the “by group” analysis regression parameters were used.
Results
Baseline characteristics
Three patients died while waiting for surgery, and were subsequently
excluded from the clinical outcome evaluation. Six patients initially
assigned to BMS implantation were instead treated by surgery, and
19 patients initially assigned to surgery were instead treated with
BMS. One patient assigned to stenting, and four patients assigned to
surgery received only medical treatment. All patients assigned to SES
implantation were treated according to protocol.
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The patient population between both trials was not matched, and
consequently the mean age of patients in the ARTS-II trial which
was 63±10 years is slightly higher than that of the patients in the
ARTS-I trial, whose mean ages were 61±9 years and 61±10 years
for CABG and PCI, respectively. The patients included in the ARTS-
II registry had more complex lesions and anatomy as has been
previously reported.16
Table 1 shows the baseline demographic and clinical
characteristics of the enrolled patients. Increasing age is associated
with an increased prevalence of diabetes mellitus, hypertension,
peripheral artery disease, previous carotid artery surgery or
cerebrovascular events, and chronic obstructive pulmonary
disease. Conversely, the incidence of hypercholesterolaemia,
obesity, family history of MI or sudden death, previous MI and
current smoking, as well as the percentage of males in the
population were found to decrease with advanced age. In all
quartiles, the majority of patients presented with stable angina.
Procedural characteristics are depicted in Table 2. As patients
included in ARTS had to be amenable for PCI or CABG, it is not
surprising that the number of lesions treated was not influenced by
age and was similar in patients assigned to CABG or stent
implantation. The left anterior descending artery was equally
Table 1. Demographics and patient characteristics (N=1,812 patients).
Q1 Q2 Q3 Q4 p-value
30-54y 54-62y 62-68y 68-83y (trend)
N=453 N=453 N=453 N=453
Men 87.2% 81.7% 73.1% 64.2% <0.001
Age (mean±sd) 48.8±4.8 58.5±2.1 65.6±1.9 73.3±3.1 <0.001
BMI (mean±sd) 27.7±3.9 27.6±3.7 27.3±3.6 26.8±4.0 <0.001
Current smoking 44.4% 25.2% 17.9% 9.8% <0.001
Diabetes mellitus 14.8% 19.6% 22.5% 24.1% <0.001
Hypertension 40.6% 51.2% 56.7% 60.7% <0.001
Hypercholesterolaemia 66.7% 63.7% 64.1% 58.3% 0.014
Family history 50.6% 42.2% 35.7% 27.5% <0.001
PVD 3.1% 4.4% 7.3% 8.6% <0.001
CVA 0.4% 0.7% 1.1% 1.8% 0.034
Previous MI 49.0% 40.2% 35.8% 36.0% <0.001
Previous CABG 0.0% 0.0% 0.0% 0.0% N/A
Previous PCI 0.9% 1.3% 2.0% 1.5% 0.29
Carotid surgery 0.0% 0.7% 1.1% 2.0% 0.002
COPD 1.5% 3.8% 6.9% 5.7% <0.001
Silent ischaemia 7.3% 7.1% 7.3% 6.6% 0.74
Stable angina 54.3% 57.6% 57.0% 54.5% 1.00
Unstable angina 38.4% 35.3% 35.8% 38.9% 0.86
1 vessel disease 2.9% 2.7% 1.8% 3.2% 0.97
2 vessel disease 63.5% 60.7% 58.2% 58.1% 0.08
3 vessel disease 33.6% 36.6% 40.0% 38.7% 0.07
LVEF (%) (mean±sd) 59.2±12.1 61.1±12.3 61.6±12.3 60.1±12.7 0.21
Lipid lowering agent 54.0% 54.3% 53.8% 52.8% 0.69
Beta blockers 67.8% 66.8% 59.0% 63.5% 0.04
ACE inhibitors 27.8% 26.3 33.9% 34.5 0.004
BMI: body mass index; PVD: peripheral vascular disease; 
CVA: cerebrovascular accident; MI: myocardial infarction; CABG: coronary
artery bypass surgery; PCI: percutaneous coronary intervention; 
COPD: chronic obstructive pulmonary disease; LVEF: left ventricular
ejection fraction; ACE: angiotensin converting enzyme
Table 2.  Angiographic and procedural characteristics 
(N=1,778 patients, N=5,404 lesions).
Q1 Q2 Q3 Q4 p-value
30-54y 54-62y 62-68y 68-83y (trend)
N=453 N=453 N=453 N=453
No. of treated lesions
(mean±sd) 2.8±1.1 2.8±1.0 2.9±1.0 2.9±1.1 0.30
Location of lesions:
RCA 32.9% 29.4% 28.6% 28.5% 0.013
LM 0.0% 0.1% 0.0% 0.1% 0.54
LAD 40.0% 40.9% 41.6% 40.7% 0.65
LCX 27.1% 29.7% 29.9% 30.8% 0.047
Lesion length
Discrete <10 mm 65.0% 64.2% 65.1% 63.6% 0.58
Tubular 10-20 mm 26.6% 26.5% 26.9% 26.7% 0.90
Diffuse >20 mm 8.4% 9.3% 8.0% 9.7% 0.46
Bifurcation or SB 33.2% 33.9% 33.7% 33.2% 0.96
Lesion classification
Type A/B1 37.2% 32.5% 31.6% 31.8% 0.003
Type B2/C 62.8% 67.5% 68.4% 68.2% 0.003
Randomised to
ARTS-I CABG 33.3% 35.1% 33.3% 31.8% 0.52
ARTS-I BMS 38.4% 31.3% 33.1% 29.6% 0.012
ARTS-II SES 28.3% 33.6% 33.6% 38.6% 0.002
In-hospital stay
Post PCI (days±sd) 3.5±2.8 3.3±2.6 4.0±4.2 3.8±3.0 0.037
Post CABG (days±sd) 8.6±3.9 8.8±3.4 10.2±5.2 10.9±6.5 <0.001
revascularised within each age subgroups and more complex
lesions were noted in older patients.
Based on the clinical and demographic data the calculated logistic
EuroSCORE for each subgroup was 1.27±0.58, 1.33±0.58, 2.07±1.10
and 3.58±1.95, respectively. Finally, the average hospital stay
increased with age and was longer among patients treated surgically.
In-hospital clinical outcome
In-hospital death and MACCE for each assigned treatment are
presented in Table 3 according to age quartile. There was an age
related increase in mortality and MACCE in patients treated
surgically. The in-hospital mortality observed in these patients was
comparable to the predicted mortality estimated by the EuroSCORE.
Conversely, age had no significant influence on the in-hospital
outcomes of patients assigned to percutaneous treatment, either
with BMS or DES. In the youngest quartile (Q1) of patients assigned
to BMS there was an excess MACCE as compared to SES PCI,
which was primarily due to the increased repeat revascularisations,
and myocardial infarctions in the BMS subgroup (p=0.016).
However, we may speculate that this observation is related to
improvements in ARTS-II PCI techniques and medical
management. In the oldest quartile (Q4) patients treated by SES PCI
had less MACCE as compared to surgically treated patients (2.3%
vs. 9.0%, p=0.011); which was predominantly driven by a
reduction in mortality (0.0% vs. 3.5%, p=0.018).
Three-year clinical outcome
Patient mortality increased with age and this trend was significant for
patients assigned to CABG and SES PCI (Table 4). A trend noted only
in those patients having PCI was the increasing incidence of
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cerebrovascular accidents with increasing age. Not surprisingly, the
need for repeat revascularisation was higher among PCI treated
patients in all age quartiles when compared to surgery. However, the
need for repeat PCI and CABG was dramatically reduced in ARTS-II
SES treated patients by 60.8%, 26.9%, 59.6% and 45.4% in Q1, Q2,
Q3 and Q4, respectively, as compared to ARTS-I BMS treated
patients. The need for repeat revascularisation was not age-
dependent.
The 3-year event free survival in each treatment arm is depicted in
Figure 1 according to age quartile. In brief, there was no significant
difference in MACCE rate between patients allocated to CABG or
SES PCI with similar outcomes noted for each age group.
Conversely, the increased need for repeat revascularisation,
specifically during the first year, resulted in a worse event free
survival for ARTS-I BMS treated patients.
Impact of age on event free survival
A multi-variable analysis was conducted to determine the influence
of age on outcome at three-years follow-up. Age together with
hypertension and multiple long diffuse lesions were independent
predictors of MACCE amongst surgically treated patients. In
patients treated with SES PCI the presence of diabetes was the
strongest independent predictor of MACCE, together with the
absence of hypertension, a small number of lesions treated, and
procedural duration (Table 5). Age was not found to be an
independent predictor of three-year outcomes amongst patients
treated by PCI either with SES or BMS.
Discussion
The current investigation is the first to evaluate long-term outcomes
of similar patients with MVD studied according to their age.
Specifically, we assessed whether PCI with BMS, PCI with SES, or
Table 3. In-hospital events (hierarchical MACCE and non
hierarchical events up to hospital discharge, per patient) counted
since date of procedure.
Q1 Q2 Q3 Q4 p-value
30-54y 54-62y 62-68y 68-83y (trend)
ARTS-I CABG N=150ⁿ N=158ⁿ N=150ⁿ N=144
MACCE % (n) 2.0 (3) 5.1 (8) 7.3 (11) 9.0 ¶(13) 0.007
Death % (n) 0.0 (0) 0.6 (1) 1.3 (2) 3.5 *(5) 0.009
CVA % (n) 0.0 (0) 2.5 (4) 0.0 (0) 1.4 (2) 0.68
MI % (n) 2.0 (3) 2.5 (4) 4.7 (7) 3.5 (5) 0.30
CABG % (n) 0.0 (0) 0.0 (0) 0.7 (1) 0.7 (1) 0.19
PCI % (n) 0.0 (0) 0.6 (1) 0.7 (1) 0.7 (1) 0.41
ARTS-I BMS N=174 N=142 N=150 N=134
MACCE % (n) 6.3 *(11) 5.6 (8) 10.7 ¶(16) 5.2 (7) 0.78
Death % (n) 0.6 (1) 1.4 (2) 1.3 (2) 0.7 (1) 0.84
CVA % (n) 0.6 (1) 0.7 (1) 0.0 (0) 1.5 (2) 0.54
MI % (n) 3.4 (6) 2.8 (4) 4.0 ¶(6) 0.7 (1) 0.28
CABG % (n) 2.3 (4) 0.7 (1) 6.7 *(10) 0.7 (1) 0.74
PCI % (n) 4.0 (7) 1.4 (2) 1.3 (2) 2.2 (3) 0.26
ARTS-II SES N=128 N=152 N=152 N=175
MACCE % (n) 0.8 (1) 2.0 (3) 3.3 (5) 2.3 (4) 0.31
Death % (n) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) N/A
CVA % (n) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) N/A
MI % (n) 0.0 (0) 1.3 (2) 0.0 (0) 1.1 (2) 0.49
CABG % (n) 0.0 (0) 0.7 (1) 1.3 (2) 1.7 (3) 0.11
PCI % (n) 0.8 (1) 0.7 (1) 2.0 (3) 0.0 (0) 0.60
*p<0.02, ¶p<0.015 vs. ARTS-II SES; n one patient died before CABG and
was not included; MACCE: major adverse cerebral and cardiovascular event;
CVA: cerebrovascular accident; MI: myocardial infarction; CABG: coronary
artery bypass graft; PCI: percutaneous coronary intervention
Table 4. Clinical endpoints at three years (hierarchical MACCE and
non hierarchical events up to 1,080 days, per patient) counted
since date of procedure.
Q1 Q2 Q3 Q4 p-value
30-54y 54-62y 62-68y 68-83y (trend)
ARTS-I CABG N=150ⁿ N=158ⁿ N=150ⁿ N=144
MACCE % (n) 7.3 (7) 17.1 (27) 18.7 (28) 21.5 (31) 0.001
Death % (n) 1.3 (1) 3.2 (5) 4.7 (7) 8.3 (12) 0.003
CVA % (n) 0.0 (0) 5.1 (8) 4.0 (6) 3.5 (5) 0.15
MI % (n) 2.7 (3) 3.8 (6) 7.3 (11) 6.3 (9) 0.07
CABG % (n) 0.7 (1) 1.3 (2) 1.3 (2) 1.4 (2) 0.57
PCI % (n) 4.0 (2) 8.2 (13) 4.7 (7) 6.9 (10) 0.56
ARTS-I BMS N=174 N=142 N=150 N=134
MACCE % (n) 32.2 *(56) 28.9 (41) 40.0 *(60) 35.1 §(47) 0.25
Death % (n) 2.9 (5) 3.5 (5) 4.7 (7) 5.2 (7) 0.25
CVA % (n) 1.7 (3) 0.7 (1) 2.7 (4) 9.0 (12) <0.001
MI % (n) 8.6 §(15) 4.9 (7) 8.7 (13) 4.5 (6) 0.34
CABG % (n) 9.2 ¶(16) 7.0 (10) 12.7 #(19) 7.5 §(10) 0.94
PCI % (n) 20.7 §(36) 19.0 (27) 20.0 ¶(30) 18.7 (25) 0.72
ARTS-II SES N=128 N=152 N=152 N=175
MACCE % (n) 13.3 (17) 20.4 (31) 17.8 (27) 24.0 (42) 0.042
Death % (n) 1.6 (2) 1.3 (2) 2.0 (3) 6.3 (11) 0.01
CVA % (n) 0.0 (0) 0.7 (1) 2.6 (4) 6.3 (11) 0.001
MI % (n) 0.8 (1) 4.6 (7) 3.3 (5) 4.0 (7) 0.63
CABG % (n) 2.3 (3) 2.6 (4) 3.3 (5) 2.3 (4) 0.4
PCI % (n) 10.9 (14) 16.4 (25) 9.9 (15) 12.0 (21) 0.72
* P<0.001; ¶P<0.02; #P<0.01; §P<0.05 vs. ARTS-II SES; MACCE: major
adverse cerebral and cardiovascular event; CVA: cerebrovascular accident;
MI: myocardial infarction; CABG: coronary artery bypass graft;
PCI: percutaneous coronary intervention
Table 5. Predictors of MACCE.
CABG SES
P Hazard ratio P Hazard ratio
Age group 0.005 1.46 0.152 1.22
Sex (female=0, male=1) 0.398 0.78 0.303 1.41
Diabetes 0.324 1.37 0.018 1.90
Hypertension 0.047 1.73 0.042 0.57
Hypercholesterolaemia 0.585 0.86 0.785 1.09
Family history 0.519 0.84 0.841 0.95
Previous vascular disease 0.057 2.21 0.458 0.64
Previous MI 0.804 1.07 0.384 0.78
Current smoker 0.403 1.31 0.060 0.40
Angina (stab/unstab/silent) 0.089 0.67 0.764 0.94
No. of diffuse lesions 
(> 20 mm) 0.001 2.35 0.394 0.83
No. of calcified lesions 0.216 0.78 0.621 1.06
No. of lesions double guidewire 0.451 0.86 0.470 1.11
No. of lesions type B2/C 0.246 0.82 0.069 1.32
No. of lesions in LAD 0.883 0.97 0.170 1.36
Duration of procedure (min.) 0.493 1.00 0.008 1.01
No. of treated lesions 0.680 1.06 <.0001 0.53
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CABG is safer and/or more effective in particular age groups. In
contrast to clinical registries, patients enrolled in the ARTS trials had
less comorbidity, and a higher proportion of complete
revascularisation.
At present the influence of age on long-term survival after PCI and
CABG has not been adequately studied. Most of the data are
derived from observational registries which doesn’t allow for a direct
comparison between PCI and CABG, as elderly patients referred to
one or the other revascularisation technique have different baseline
characteristics. However a recent registry, which corrected for
baseline differences, has shown a trend towards a better survival
following surgery, despite the less invasive nature of PCI, and the
lower initial morbidity.17,18
There is a limited amount of data available from randomised trials
on the influence of age on patient outcome after revascularisation.
The BARI and SoS trial showed that survival was better with CABG
compared with PCI irrespective of age.19,20 Conversely, a systematic
review has shown that long term survival after PCI or CABG is
similar among patients over the age of 65 when compared to those
younger than 65.21
Increasing age is associated with a lower three years survival among
patients enrolled in CABG or SES arms of ARTS trials. However,
neither PCI vs. CABG nor DES vs. BMS have a significant impact on
survival up to three years, within each age quartiles. 
This study has reiterated that important clinical and angiographic
characteristics are age related. Older patients are more likely to be
female, and when compared to their younger counterparts they are
more likely to have comorbidities such as diabetes and
hypertension.1-4 Furthermore, the elderly have more diffuse and
complex coronary lesions on angiography.22,23 Therefore, in real-
world clinical practice, when myocardial revascularisation is
required, these important clinical characteristics are used on a
case-by-case basis to make a clinical decision, without any well-
established criteria for identifying those elderly patients more likely
to benefit from PCI or CABG. Currently elderly patients with
significant comorbidities tend to be treated by PCI, not only because
it is less invasive, but also based on the results from the AWESOME
randomised trial which demonstrated similar survival outcomes in
patients >70 years of age following either PCI or CABG.24
The data from the ARTS-I trial confirms a gradual increase of both
mortality (p=0.003) and morbidity (p=0.001) with age amongst
patients referred for CABG. Although the death rate also increased
with increasing age among ARTS-II patients (p=0.01), age (as
assessed per quartile) was not an independent predictor of MACCE
following PCI (p=0.15), whilst it did emerge as an important
independent predictor of MACCE following surgery (p=0.005). The
selection of patients without severe comorbidities, with preserved
left ventricular function and amenable to (near) complete
revascularisation by PCI is the most likely explanation of the
excellent results observed after stenting, particularly amongst those
treated with SES. Those patients having surgery also had similar
baseline characteristics, and were low surgical risk based on their
Figure 1. Kaplan-Meier curve to three years showing freedom from major adverse cardiac and cerebrovascular event (MACCE) according to age
quartile in patients assigned to coronary artery bypass surgery (CABG), percutaneous coronary angioplasty with bare metal stent (BMS) and
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calculated EuroSCORE. Therefore this study demonstrates that the
impact of age on the outcomes after coronary revascularisation for
MVD is significantly more important after surgery than after PCI.
Our data show that the risk from surgery is highest during the in-
hospital phase. Notably, the eldest patients (>68 years) undergoing
surgery had a higher mortality rate than their counterparts treated
by SES PCI. The in-hospital mortality observed in ARTS-I among
surgically treated patients is in line with their predicted mortality
based on the EuroSCORE. For patients included in the fourth
quartile, the EuroSCORE predicted in-hospital mortality was of
3.58%, which is almost identical to that actually observed in this
study (3.5%). For the younger age groups, the observed in-hospital
mortality was slightly lower than that predicted by the EuroSCORE
(0.0% vs. 1.27%, 0.6% vs. 1.33% and 1.3% vs. 2.07% for Q1, Q2
and Q3). These results are in keeping with recent evidence which
suggests that the logistic EuroSCORE over estimates mortality, and
requires recalibration.25 The SYNTAX trial has also shown that early
outcomes after PCI are related to initial lesion characteristics,
however new evidence also suggests that these early outcomes after
PCI can be influenced by adverse patient characteristics as
assessed by the EuroSCORE.26,27
Clearly, the late outcomes after PCI are determined by the need for
repeat revascularisation. At three-year follow-up, 173, 39 and 89
repeat revascularisations with PCI and/or surgery were performed in
the ARTS-I PCI, ARTS-I CABG and ARTS-II PCI patients,
respectively. Consistent with other trials of DES the use of SES lead
to a dramatic improvement in the results of PCI in MVD as
compared to BMS PCI.28 This improvement has now been shown in
our study to be independent of age. Despite the significantly lower
repeat intervention rates with SES, CABG still remains associated
with the lowest re-intervention rates in any age group quartile.
Previous studies have shown that diabetes is a strong predictor of
adverse outcome among patients treated by PCI, most notably for
those with MVD.29,30 Our results confirm that diabetes is the most
important clinical risk factor for MACCE in patients treated by SES
PCI. In the surgical group diabetes was not associated with MACCE,
which is in contrast to previous observational studies which have
shown diabetes to be an independent predictor of mortality.31-33 The
relative safety and efficacy of CABG decreases with increasing age,
and this is independent of a patient’s diabetic status. This data
therefore suggests that young patients with diabetes benefit the
most from surgery, and conversely, elderly patients without diabetes
have a better outcome following SES PCI, compared to CABG.
This implies that in diabetic patients with MVD, amenable to both
PCI and CABG, a patient’s age should be considered when deciding
the most appropriate method of revascularisation. In view of the
paucity of evidence this subject needs to be accurately assessed in
a specifically designed clinical trial in diabetic patients. Currently
there are no published randomised studies of revascularisation
specifically in diabetics; previous data have all been derived from
post hoc subgroup analysis. Recently the early results of the
CARDia trial, the first dedicated randomised trial of
revascularisation in diabetics, showed no difference in outcome
between diabetic patients with MVD treated with PCI or CABG,34
although no age distributions have yet been released. The full
publication of CARDia is awaited, together with the results of the on-
going FREEDOM trial with the specific aim to clarify the role of
CABG and PCI in diabetic patients with MVD. In the BARI 2D trial,
Frye et al35 reported that for many patients with both diabetes and
coronary artery disease, optimal medical therapy rather than any
intervention is an excellent first-line strategy, notably for those with
less severe disease. When revascularisation by PCI is indicated, five
year MACE free survival is not affected by the initial treatment
strategy (medical or revascularisation). However, when
revascularisation by CABG is deemed the more appropriate
revascularisation strategy, MACE free survival is better in patients
initially randomised to surgery. This trial also indicates that
treatment strategy must be individualised for specific patients,
based on the most appropriate evidence-based treatment
recommendations.
Study limitations
Firm conclusions regarding the advisability of SES PCI in the oldest
patients with multivessel disease cannot be drawn from the
comparative evaluation of the ARTS-I and ARTS-II trials. Moreover,
these data refer to selected patients with low co-morbidities, who
were amenable to complete revascularisation with either PCI or
CABG; importantly very old patients (octogenarians) were excluded
from this study.
This study combines results of a randomised trial (ARTS I) and a
registry (ARTS-II). Population of the registry was comparable (in
term of inclusion criteria) but “not matched” besides a similar 2/3
MVD ratio. We sought that age-corrected or propensity analysis
would not be appropriate for the pooled ARTS-I and II population
analysis. We therefore aimed to compare outcomes according to
age quartile. However, using this approach, clinical and anatomical
differences between patient’s arms of each quartile are not fully
compensated.
An important limitation to consider is the long time lag between the
enrolment of patients in ARTS-I and ARTS-II, which may have
influenced outcomes. The development of new surgical techniques
and increasing use of arterial conduits may of lead to improved
surgical outcomes if the CABG patients had been enrolled at the
same time as ARTS-II SES patients. Conversely the patients in
ARTS-II had a worse baseline and procedural risk profile compared
to those included in ARTS-I, however better stent design, improved
PCI technique and equipment, as well as the increased use of anti-
platelet agents probably account for the improved procedural
success in these patients.
Clinical implications
Increasing age has an adverse prognosis in MVD patients treated by
CABG which is not observed following percutaneous
revascularisation. The use of SES has improved the results of PCI
such that they are now as good as those of surgery for any age
quartile, furthermore this use of SES is not associated with an
excess in post discharge death or MI as compared to BMS. At
present multivessel PCI with SES in elderly patients is a valuable
alternative to surgery, particular in the absence of diabetes.
Whether SES PCI is equivalent to CABG, or even superior in elderly
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patients without diabetes, needs to be formally demonstrated in a
head to head randomised trial, with long-term follow-up to help
define the optimal treatment of these patients.
Conclusions
Age seems to influence the CABG outcome in-hospital but not PCI.
PCI-SES could offer lower immediate risk in patients with MVD and
comparable long-term outcome as CABG especially in older
patients. The worst outcome of PCI-BMS group is primarily related
to the need for repeat revascularisation. Diabetes is the most
important predictor of MACCE following PCI.
References
1. Peterson ED, Alexander KP, Malenka DJ, Hannan EL, O’Conner GT,
McCallister BD, Weintraub WS, Grover FL. Multicenter experience in
revascularization of very elderly patients. Am Heart J 2004;148:486-92.
2. Weintraub WS. Coronary operations in octogenarians: can we select
the patients? Ann Thorac Surg 1995;60:875-6.
3. Batchelor WB, Anstrom KJ, Muhlbaier LH, Grosswald R,
Weintraub WS, O’Neill WW, Peterson ED. Contemporary outcome trends
in the elderly undergoing percutaneous coronary interventions: results in
7,472 octogenarians. National Cardiovascular Network Collaboration. 
J Am Coll Cardiol 2000;36:723-30.
4. Alexander KP, Anstrom KJ, Muhlbaier LH, Grosswald RD,
Smith PK, Jones RH,Peterson ED. Outcomes of cardiac surgery in
patients >or=80 years: results from the National Cardiovascular Network. 
J Am Coll Cardiol 2000;35:731-8.
5. Mullany CJ, Mock MB, Brooks MM, Kelsey SF, Keller NM, 
Sutton-Tyrrell K,Detre KM, Frye RL. Effect of age in the Bypass
Angioplasty Revascularization Investigation (BARI) randomized trial. 
Ann Thorac Surg 1999;67:396-403.
6. Legrand VM, Serruys PW, Lindeboom WK, Vrolix MD, Fransen GM,
Materne PH,Dekoster G, Seabra-Gomes R, Queiroz E Melo J. Influence of
Age on the Outcomes of Percutaneous and Surgical Treatment of
Multivessel Coronary Artery Disease Patients: Results from the Multicentre
Randomized Arterial Revascularization Therapy Study. Geriatrics & Aging
2002;5:9-16.
7. Garza JJ, Gantt DS, Van Cleave H, Riggs MW, Dehmer GJ. Hospital
disposition and long-term follow-up of patients aged >/=80 years under-
going coronary artery revascularization. Am J Cardiol 2003;92:590-2.
8. Liistro F, Angioli P, Falsini G, Ducci K, Baldassarre S, Burali A,
Bolognese L. Early invasive strategy in elderly patients with non-ST eleva-
tion acute coronary syndrome: comparison with younger patients regard-
ing 30 day and long term outcome. Heart 2005;91:1284-8.
9. Graham MM, Ghali WA, Faris PD, Galbraith PD, Norris CM,
Knudtson ML. Survival after coronary revascularization in the elderly.
Circulation 2002;105:2378-84.
10. Trial of invasive versus medical therapy in elderly patients with
chronic symptomatic coronary-artery disease (TIME): a randomised trial.
Lancet 2001;358:951-7.
11. Pfisterer M, Buser P, Osswald S, Allemann U, Amann W,
Angehrn W, Eeckhout E, Erne P, Estlinbaum W, Kuster G, Moccetti T,
Naegeli B, Rickenbacher P. Outcome of elderly patients with chronic
symptomatic coronary artery disease with an invasive vs optimized med-
ical treatment strategy: one-year results of the randomized TIME trial.
JAMA 2003;289:1117-23.
12. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ,
Schonberger JP,Buller N, Bonser R, van den Brand MJ,
van Herwerden LA, Morel MA, van Hout BA. Comparison of coronary-
artery bypass surgery and stenting for the treatment of multivessel dis-
ease. N Engl J Med 2001;344:1117-24.
13. Serruys PW, Ong AT, Morice MC, De Bruyne B, Colombo A,
Macaya C,Richardt G, Fajadet J, Hamm C, Dawkins K, O’Malley J,
Bressers M, Dohonoe D on behalf of the ARTS II investigators. Arterial
Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the
treatment of patients with Multivessel de novo coronary artery lesions.
EuroIntervention 2005;1:147-156.
14. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC,
Fransen GM,Nielsen TT, Paulsen PK, Seabra Gomes R, de Queiroz e Melo
JMG, Marques dos Santos Neves JP, Lindeboom W, Backx B. Three-year
outcome after coronary stenting versus bypass surgery for the treatment
of multivessel disease. Circulation 2004;109:1114-20.
15. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A,
Bonnier JJ, Schönberger JPMA, Buller N, Bonser R, Disco C, Backx B,
Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary
stenting versus bypass surgery for the treatment of multivessel disease:
the final analysis of the Arterial Revascularization Therapies Study (ARTS)
randomized trial. J Am Coll Cardiol 2005;46:575-81.
16. Serruys PW, Daemen J, Morice MC, DeBruyne B, Colombo A,
Macaya C, Richardt G, Fajadet J, Hamm C, Dawkins KD, Vranckx P,
Bressers M, van Domburg R, Schuijer M, Wittebols K, Pieters M, Stoll HP.
Three-year follow-up of the ARTS-II - sirolimus-eluting stents for the treat-
ment of patients with multivessel coronary artery disease. EuroIntervention
2008;3:450-459.
17. Rodes-Cabau J, Deblois J, Bertrand OF, Mohammadi S, Courtis J,
Larose E,Dagenais F, Déry JP, Mathieu P, Rousseau M, Barbeau G,
Baillot R, Gleeton O, Perron J, Nguyen CM, Roy L, Doyle D De
Larochellière R, Bogaty P, Voisine P. Nonrandomized comparison of coro-
nary artery bypass surgery and percutaneous coronary intervention for the
treatment of unprotected left main coronary artery disease in octogenari-
ans. Circulation 2008;118:2374-81.
18. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S,
Ehara N,Taniguchi R, Doi T, Nishiyama K, Ozasa N, Saito N, Hoshino K,
Mitsuoka H, Abe M, Toma M, Tamura T, Haruna Y, Imai Y, Teramukai S,
Fukushima M, Kita T. Long-term outcomes of coronary-artery bypass graft
surgery versus percutaneous coronary intervention for multivessel coro-
nary artery disease in the bare-metal stent era. Circulation 2008;118(14
Suppl):S199-209.
19. Comparison of coronary bypass surgery with angioplasty in patients
with multivessel disease. The Bypass Angioplasty Revascularization
Investigation (BARI) Investigators. N Engl J Med 1996;335:217-25.
20. Zhang Z, Mahoney EM, Spertus JA, Booth J, Nugara F, Kolm P,
Stables RH, Weintraub WS. The impact of age on outcomes after coronary
artery bypass surgery versus stent-assisted percutaneous coronary inter-
vention: one-year results from the Stent or Surgery (SoS) trial. Am Heart J
2006;152:1153-60.
21. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV,
Varghese R, Kapoor JR, Ardehali R, Owens DK, Hlatky MA. Systematic
Review: The Comparative Effectiveness of Percutaneous Coronary
Interventions and Coronary Artery Bypass Graft Surgery. Annals of Internal
Medicine 2007;147:703-9.
22. Shirani J, Alaeddini J, Roberts WC. Comparison of modes of death
and cardiac necropsy findings in fatal acute myocardial infarction in men
and women >75 years of age. Am J Cardiol 2000;86:1010-2,A8,A10.
144_20090615_02_Legrand_AOP_June_OK838  14/01/11  16:59  Page844
- 845 -
Clinical research
23. Hirsch H, Lazar J, Marzo KP, Steingart RM. Percutaneous revascular-
ization for unstable angina in the elderly. Coron Artery Dis 2000;11:315-22.
24. Ramanathan KB, Weiman DS, Sacks J, Morrison DA, Sedlis S,
Sethi G, Henderson WG. Percutaneous intervention versus coronary
bypass surgery for patients older than 70 years of age with high-risk unsta-
ble angina. Ann Thorac Surg 2005;80:1340-6.
25. Bhatti F, Grayson AD, Grotte G, Fabri BM, Au J, Jones M,
Bridgewater B. The logistic EuroSCORE in cardiac surgery: how well does
it predict operative risk? Heart 2006;92:1817-1820.
26. Romagnoli E, Burzotta F, Trani C, Siviglia M, Biondi-Zoccai GG,
Niccoli G,Leone AM, Porto I, Mazzari MA, Mongiardo R, Rebuzzi AG,
Schiavoni G, Crea F. EuroSCORE as predictor of in-hospital mortality after
percutaneous coronary intervention. Heart 2009;95:43-8.
27. Serruys PW. The Synergy between Percutaneous Coronary
Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study.
Primary Endpoint Results at One Year in the Randomized Cohort- TCT
presentation, Washington. 2008.
28. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC,
Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ,
Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M,
Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ,
Diem P, Meier B, Zwahlen M, Reichenbach S, Telle S, Windecker S,
Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a
collaborative network meta-analysis. Lancet 2007;370:937-48.
29. The final 10-year follow-up results from the BARI randomized trial.
J Am Coll Cardiol 2007;49:1600-6.
30. Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D,
Sheiban I, Suttorp MJ, Vrancks P, Rademaker T, Goedhart D, Schuijer M,
Wittebols K, Macours N, Stoll HP, Serruys PWl. Multivessel coronary
revascularization in patients with and without diabetes mellitus 3-year fol-
low-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II)
trial. J Am Coll Cardiol 2008;52:1957-67.
31. Adler DS, Goldman L, O’Neil A, Cook EF, Mudge GH, Jr.,
Shemin RJ, DiSesa V, Cohn LH, Collins JJ. Long-term survival of more
than 2,000 patients after coronary artery bypass grafting. Am J Cardiol
1986;58:195-202.
32. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM,
Jones EL, Guyton RA. Influence of diabetes mellitus on early and late out-
come after coronary artery bypass grafting. Ann Thorac Surg
1999;67:1045-52.
33. Herlitz J, Wognsen GB, Emanuelsson H, Haglid M, Karlson BW,
Karlsson T, Albertsson P, Westberg S. Mortality and morbidity in diabetic
and nondiabetic patients during a 2-year period after coronary artery
bypass grafting. Diabetes Care 1996;19:698-703.
34. Kapur A. Coronary Artery Revascularisation in Diabetes. The
CARDia trial. Presentation at European Society of Cardiology meeting
September 1st 2008.
35. The BARI 2D Study Group. A randomized trial of therapies for type
2 diabetes and coronary artery disease. N Engl J Med 2009;360: 2503-15.
144_20090615_02_Legrand_AOP_June_OK838  14/01/11  16:59  Page845
